Teva's Sicor reaquires US marketing rights to kidney dialysis treatment

The calcitriol injection vial is used primarily to treat chronic kidney dialysis patients.

aaiPharma Inc. (AAII) today announced that Sicor Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA; TASE:TEVA), has reacquired its US marketing rights for calcitriol injection in exchange for certain payments to aaiPharma.

Additional details were not disclosed.

Calcitriol injection vial is a drug used primarily to treat chronic kidney dialysis patients with abnormally low levels of calcium in their blood.

aaiPharma Inc. is a science-based pharmaceutical company focused on pain management, with corporate headquarters in Wilmington, North Carolina.

Published by Globes [online], Israel business news - - on Thursday, December 23, 2004

View comments in rows
Update by email about comments talkback
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018